PIPELINE

Global Leader of Cancer Treatments

ATB-301

Product outline

ATB-301 is a new drug candidate for Combined anti-cancer treatment of
TGF-β selective inhibitor, TGF-β2 Targeting Antisense Oligonucleotide (ASO) and IL-2

pipeline
TGF-β2 Targeting ASO
18-mer phosphorothioate ASO (Antisense-Oligo) nucleotide new drug targeting human TGF-β
Designed based on the correlation between TGF-β overexpression and tumor progression
in-vitro/in-vivo/clinical efficacy data available on single therapies for pancreatic cancer, melanoma, glioblastoma
In-vitro test : Verified synergistic effect by TGF-β2 Targeting ASO +IL-2 combination therapy on breast cancer cell line (SK-BR-3, MD-MB-231), Pancreatic cancer cell line (HUP-T3, PA-TU-8902), Lung cancer cell line (A549).
In-vivo test: Verified synergistic effect by TGF-β2 Targeting ASO +IL-2 combination therapy on humanized mouse (NSG mouse model) using Lung cancer cell line (A549) xenograft model with TGF-β2 Targeting ASO + IL-2 activated PBMC (Peripheral Blood Mononuclear Cells)
Increased tumor cell deaths induced by TGF-β2 Targeting ASO +IL-2 in solid tumor cell line was confirmed

Pharmacological mechanism and evidence of combination therapy

  • Problem
    Immuno-oncology drugs are effective, but their response rate varies greatly upon cancer type
    TGF-β has been found to be the main cause of resistance to immuno-oncology drugs.
  • Solution
    Improving response rate in various cancer types by combined therapy
    Increasing treatment effect by using the substances inhibiting TGF-β

Combination therapy

Combined therapy

Pipeline expandability

TGF-β2 Targeting ASO combination therapy with PD-1/PD-L1 or CTLA-4 immuno-oncology ▶ ATB-302, 303

Pipeline expandability
New drug development of TGF-β2 Targeting ASO + Immunotherapy combination
  • Strong tumor suppression result by TGF-β2 Targeting ASO + Immune check point inhibitor combination therapy
  • In-vivo test with a global CRO for synergistic effect by the combined therapy of TGF-β2 Targeting ASO + IL-2 based on above in-vivo and in-vitro studies followed by IND application for clinical trial P1